Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07390643 · ClinicalTrials.gov registry record · NA
The DISCOVER Study
A NA study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT07390643: Clinical Trial NA study, sponsored by Dana-Farber Cancer Institute.
NCT07390643 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07390643, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the possible benefits of screening with an investigational, but commercially available blood test designed to detect many types of cancer. The name of the screening blood test being studied is: -GRAIL Galleri MCED test
Primary Outcome
MCED positive cancer type is defined as the type of cancer detected by the MCED test. Cancer type will be defined and recorded using ICD-O-3 codes for primary anatomic site (topography) and histology (morphology).
Interventions
- DEVICE GRAIL Galleri MCED test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
What is known before NCT07390643 opens enrollment
NCT07390643 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which GRAIL Galleri MCED test is the first listed.
NCT07390643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07390643 about?
NCT07390643 is a clinical study titled "The DISCOVER Study". The purpose of this research study is to evaluate the possible benefits of screening with an investigational, but commercially available blood test designed to detect many types of cancer. The name of the screening blood test being studied is: -GRAIL Galleri MCED test
What is the current status of trial NCT07390643?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-07. Estimated completion is 2028-01-31.
What interventions are being tested in trial NCT07390643?
The interventions under investigation include: GRAIL Galleri MCED test (DEVICE).
Who is sponsoring clinical trial NCT07390643?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07390643's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia